The Re-Emergence of Device Reprocessing
The single-use device reprocessing and remanufacturing market is an estimated $200+ million business and growing fast thanks to cost containment pressures and the waning of early controversy surrounding the practice. By nearly any measure--including the number of facilities, number of approved products, and dollars both spent and saved--the SUD reprocessing industry is making a noteworthy impact on health care delivery in the US.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.